A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO® VERSUS PLACEBO IN COMBINATION WITH PHESGO® AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA‑MUTATED HER2‑POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • White, Michelle (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date26/07/24 → 25/07/29

Clinical Trial Phase

  • Phase III (a & b)